Patents Assigned to Oncolmmune, Inc.
  • Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
    Publication number: 20220098278
    Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
    Type: Application
    Filed: September 30, 2021
    Publication date: March 31, 2022
    Applicants: Oncolmmune, Inc., Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Ning Li
  • METHODS OF SELECTING AND DESIGNING SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODIES FOR CANCER THERAPY
    Publication number: 20210047410
    Abstract: The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 18, 2021
    Applicants: Oncolmmune, Inc., Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS
    Publication number: 20210040212
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 11, 2021
    Applicants: Oncolmmune, Inc., University of Maryland, Baltimore
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20190016783
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: August 16, 2018
    Publication date: January 17, 2019
    Applicant: ONCOLMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Uses of hypoxia-inducible factor inhibitors
    Patent number: 9623070
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: April 18, 2017
    Assignee: Oncolmmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 9611309
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: April 4, 2017
    Assignee: Oncolmmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20150239953
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: October 21, 2014
    Publication date: August 27, 2015
    Applicant: Oncolmmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng